-
Mashup Score: 2Angelman Syndrome Clinical Study Showing Promise | CheckRare.com - 4 year(s) ago
Angelman syndrome is a rare neurodevelopmental disorder caused by a genetic mutation – usually a mutation in the ubiquitin protein ligase E3a (UBE3A) gene – that leads to a reduction in UBE3A protein.
Source: CheckRare.comCategories: Latest Headlines, Rare DiseaseTweet
-
Mashup Score: 2
As genetic sequencing becomes more widespread, a disconnect is emerging between what individual patients expect to get back and what scientists are willing and able to tell them. WSJ visited MIT’s Broad Institute to learn about the murky world of genomic research data. Photo: Angela Weiss/AFP via Getty Images
Source: www.wsj.comCategories: Latest Headlines, Rare DiseaseTweet-
What Patients Fail to Understand When They Sign Up for Genetic Studies https://t.co/33fzCQ5wiF
-
-
Mashup Score: 2
As genetic sequencing becomes more widespread, a disconnect is emerging between what individual patients expect to get back and what scientists are willing and able to tell them. WSJ visited MIT’s Broad Institute to learn about the murky world of genomic research data. Photo: Angela Weiss/AFP via Getty Images
Source: www.wsj.comCategories: Latest Headlines, Rare DiseaseTweet-
What Patients Fail to Understand When They Sign Up for Genetic Studies https://t.co/33fzCQ5wiF
-
-
Mashup Score: 2
As genetic sequencing becomes more widespread, a disconnect is emerging between what individual patients expect to get back and what scientists are willing and able to tell them. WSJ visited MIT’s Broad Institute to learn about the murky world of genomic research data. Photo: Angela Weiss/AFP via Getty Images
Source: www.wsj.comCategories: Latest Headlines, Rare DiseaseTweet-
What Patients Fail to Understand When They Sign Up for Genetic Studies https://t.co/33fzCQ5wiF
-
-
Mashup Score: 2
As genetic sequencing becomes more widespread, a disconnect is emerging between what individual patients expect to get back and what scientists are willing and able to tell them. WSJ visited MIT’s Broad Institute to learn about the murky world of genomic research data. Photo: Angela Weiss/AFP via Getty Images
Source: www.wsj.comCategories: Latest Headlines, Rare DiseaseTweet-
What Patients Fail to Understand When They Sign Up for Genetic Studies https://t.co/33fzCQ5wiF
-
-
Mashup Score: 2
As genetic sequencing becomes more widespread, a disconnect is emerging between what individual patients expect to get back and what scientists are willing and able to tell them. WSJ visited MIT’s Broad Institute to learn about the murky world of genomic research data. Photo: Angela Weiss/AFP via Getty Images
Source: www.wsj.comCategories: Latest Headlines, Rare DiseaseTweet-
What Patients Fail to Understand When They Sign Up for Genetic Studies https://t.co/33fzCQ5wiF
-
-
Mashup Score: 2
As genetic sequencing becomes more widespread, a disconnect is emerging between what individual patients expect to get back and what scientists are willing and able to tell them. WSJ visited MIT’s Broad Institute to learn about the murky world of genomic research data. Photo: Angela Weiss/AFP via Getty Images
Source: www.wsj.comCategories: Latest Headlines, Rare DiseaseTweet-
What Patients Fail to Understand When They Sign Up for Genetic Studies https://t.co/33fzCQ5wiF
-
-
Mashup Score: 2
As genetic sequencing becomes more widespread, a disconnect is emerging between what individual patients expect to get back and what scientists are willing and able to tell them. WSJ visited MIT’s Broad Institute to learn about the murky world of genomic research data. Photo: Angela Weiss/AFP via Getty Images
Source: www.wsj.comCategories: Latest Headlines, Rare DiseaseTweet-
What Patients Fail to Understand When They Sign Up for Genetic Studies https://t.co/33fzCQ5wiF
-
-
Mashup Score: 2
As genetic sequencing becomes more widespread, a disconnect is emerging between what individual patients expect to get back and what scientists are willing and able to tell them. WSJ visited MIT’s Broad Institute to learn about the murky world of genomic research data. Photo: Angela Weiss/AFP via Getty Images
Source: www.wsj.comCategories: Latest Headlines, Rare DiseaseTweet-
What Patients Fail to Understand When They Sign Up for Genetic Studies https://t.co/33fzCQ5wiF
-
-
Mashup Score: 2
As genetic sequencing becomes more widespread, a disconnect is emerging between what individual patients expect to get back and what scientists are willing and able to tell them. WSJ visited MIT’s Broad Institute to learn about the murky world of genomic research data. Photo: Angela Weiss/AFP via Getty Images
Source: www.wsj.comCategories: Latest Headlines, Rare DiseaseTweet-
What Patients Fail to Understand When They Sign Up for Genetic Studies https://t.co/33fzCQ5wiF
-
Dr. Amit Rahkit, CMO at Ovid Therapeutics Inc. discusses OV101, a GABAA agonist that is showing promise in clinical trials for Angelman syndrome. @OvidRx @angelman @AngelmanUK Angelman Syndrome International Angelman Day https://t.co/ejMNg9HHVz